Erschienen in:
01.09.2010 | Original Article
Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy
verfasst von:
Tatsuya Ide, Michio Sata, Kazuaki Chayama, Michiko Shindo, Joji Toyota, Satoshi Mochida, Eiichi Tomita, Hiromitsu Kumada, Gotaro Yamada, Hiroshi Yatsuhashi, Norio Hayashi, Hiroki Ishikawa, Taku Seriu, Masao Omata
Erschienen in:
Hepatology International
|
Ausgabe 3/2010
Einloggen, um Zugang zu erhalten
Abstract
Purpose
Current Japanese guidelines recommend that patients should be switched from lamivudine to entecavir when they meet certain criteria. This analysis examines the efficacy and safety of long-term entecavir therapy in patients who were switched to entecavir after 24 weeks’ lamivudine therapy in Japanese studies ETV-047 and ETV-060.
Methods
The Phase II Japanese study ETV-047 assessed the efficacy of different entecavir doses when compared with lamivudine. A total of 33 Japanese patients who received lamivudine 100 mg daily in ETV-047 entered the open-label rollover study ETV-060 and subsequently received treatment with entecavir 0.5 mg daily. Hepatitis B virus (HBV) DNA suppression, alanine aminotransferase (ALT) normalization, hepatitis B e antigen (HBeAg) seroconversion, and resistance were evaluated among patients with available samples for up to 96 weeks. Safety was assessed throughout the treatment period.
Results
After 96 weeks of entecavir therapy in ETV-060, 90% of patients achieved HBV DNA <400 copies/mL as compared to 21% of patients who completed 24 weeks of lamivudine therapy in ETV-047. Increasing proportions of patients achieved ALT normalization and HBeAg seroconversion following long-term entecavir treatment. No patients experienced virologic breakthrough, and substitutions associated with entecavir resistance were not observed in patients with detectable HBV DNA. Entecavir was well tolerated during long-term treatment.
Conclusions
Switching lamivudine-treated patients with chronic hepatitis B to entecavir results in increased virologic suppression with no evidence of resistance through 2 years of entecavir therapy. These findings support recommendations in the current Japanese treatment guidelines that stable lamivudine patients should be switched to entecavir.